https://orcid.org/0000-0001-8676-6063
References
- Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273. doi:10.1038/s41586-020-2012-732015507
- World Health Organization: WHO. The true death toll of COVID-19: estimating global excess mortality [Internet]; 2020. Available from: https://www.who.int/data/stories/the-true-death-toll-of-covid-19-estimating-global-excess-mortality. Accessed November 16, 2021.
- Gavi. The COVID-19 vaccine race – weekly update [Internet]; 2021. Available from: https://www.gavi.org/vaccineswork/covid-19-vaccine-race. Accessed November 16, 2021.
- Choi EM. COVID-19 vaccines for low- and middle-income countries. Transactions of The Royal Society of Tropical Medicine and Hygiene. 2021;115(5):447-456. doi:10.1093/trstmh/trab045
- Ebinger JE, Fert-Bober J, Printsev I, et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat Med. 2021;27(6):981–984. doi:10.1038/s41591-021-01325-633795870
- Callaway E. Mix-and-match COVID vaccines trigger potent immune response. Nature. 2021;593(7860):491. doi:10.1038/d41586-021-01359-334012131
- Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2020;396(10267):1979–1993. doi:10.1016/S0140-6736(20)32466-133220855
- Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111. doi:10.1016/S0140-6736(20)32661-133306989
- AstraZeneca. COVID-19 vaccine AstraZeneca real-world evidence summary; August, 2021:38–39. Available from: https://www.astrazeneca.com/content/dam/az/covid-19/media/factsheets/COVID-19_Vaccine_AstraZeneca_Real-World_Evidence_Summary.pdf. Accessed November 16, 2021.
- World Health Organization: WHO. Bangladesh COVID-19 reported to WHO [Internet]; 2021. Available from: https://covid19.who.int/region/searo/country/bd. Accessed November 16, 2021.
- Callegaro A, Borleri D, Farina C, et al. Antibody response to SARS‐CoV‐2 vaccination is extremely vivacious in subjects with previous SARS‐CoV‐2 infection. J Med Virol. 2021;93(7):4612–4615. doi:10.1002/jmv.2698233788281
- Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467–478. doi:10.1016/S0140-6736(20)31604-432702298
- Ewer KJ, Barrett JR, Belij-Rammerstorfer S, et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med. 2021;27(2):270–278. doi:10.1038/s41591-020-01194-533335323
- Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020;383(25):2427–2438. doi:10.1056/NEJMoa202843632991794
- Pottegard A, Lund LC, Karlstad Ø, et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. BMJ. 2021;373. doi:10.1136/bmj.n1114